All In Biotech

Drug Trial Radar · NCT07135986

Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children and Adolescents in China

A Phase 3, Modified Double-blind, Multi-center Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children and Adolescents (2 to 17 Years of Age) in China

Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,602 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,602

Actual

Start

Sep 26, 2025

Primary completion

May 1, 2026

Study completion Sep 24, 2026

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Aug 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 17 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 3, modified double-blind, randomized, parallel-group, active-controlled, multicenter study with 2 arms and 4 groups to evaluate the immunogenicity and safety of MenACYW conjugate vaccine in children and adolescents versus control meningococcal vaccines licensed in China. Study details include: * The study duration will be approximately 180 days. * The vaccination visit will be Visit 1. * The visit frequency will be 2 on-site visits with a 30-day interval. A safety visit/telephone call is planned on the ninth day after the vaccination for all groups; a safety follow-up telephone call is planned for all groups 180 days post the last vaccination.

Conditions

  • Meningococcal Infection
  • Healthy Volunteers

Interventions

  • MenACYW conjugate vaccineBiological

    Pharmaceutical form:Liquid solution-Route of administration:Intramuscular (IM) injection

  • MenACYW135 polysaccharide vaccineBiological

    Pharmaceutical form: Lyophilized powder-Route of administration:IM injection

  • MenAC conjugate vaccineBiological

    Pharmaceutical form:Lyophilized powder-Route of administration:IM injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Participants 7 through 17 years of age (Cohort I): Vaccine seroresponse to meningococcal serogroups A, C, Y, and WTime frame: Day 01 (pre-vaccination) and Day 31 (post- vaccination)
  2. Participants 7 through 17 years of age (Cohort I): Geometric mean titers (GMTs) of antibodies against meningococcal serogroups A, C, Y, and WTime frame: Day 31 (post- vaccination)
  3. Participants 7 through 17 years of age (Cohort I): Vaccine seroresponse to meningococcal serogroups W and Y will be assessed in participants receiving MenACYW conjugate vaccineTime frame: Day 01 (pre-vaccination) and Day 31 (post- vaccination)
  4. Participants 2 through 6 years of age (Cohort II): Vaccine seroresponse to meningococcal serogroups A and CTime frame: Day 01 (pre-vaccination) and Day 31 (post- vaccination)
  5. Participants 2 through 6 years of age (Cohort II): Geometric mean titers (GMTs) of antibodies against meningococcal serogroups A and CTime frame: Day 01 (pre-vaccination) and Day 31 (post- vaccination)
  6. Participants 2 through 6 years of age (Cohort II): Vaccine seroresponse to meningococcal serogroups W and Y in participants receiving MenACYW conjugate vaccineTime frame: Day 01 (pre-vaccination) and Day 31 (post- vaccination)

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Investigational Site Number : 1561001

    Jingxi, China

  • Investigational Site Number : 1561003

    Liuzhou, China

  • Investigational Site Number : 1561002

    Tengzhou, China

  • Investigational Site Number : 1561000

    Nanning, Guangxi, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.